[go: up one dir, main page]

PE20050681A1 - PIRIDO[2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2 - Google Patents

PIRIDO[2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2

Info

Publication number
PE20050681A1
PE20050681A1 PE2005000028A PE2005000028A PE20050681A1 PE 20050681 A1 PE20050681 A1 PE 20050681A1 PE 2005000028 A PE2005000028 A PE 2005000028A PE 2005000028 A PE2005000028 A PE 2005000028A PE 20050681 A1 PE20050681 A1 PE 20050681A1
Authority
PE
Peru
Prior art keywords
pyrido
pyrimidin
pyrid
pde
diamines
Prior art date
Application number
PE2005000028A
Other languages
English (en)
Inventor
Robert James Chambers
Kelvin Lam
Thomas Arthur Beyer
Andrew Ian Morrell
Mei Li
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20050681A1 publication Critical patent/PE20050681A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I DONDE R1 Y R2 SON CADA UNO H, METOXI; n ES 1-4; X ES UN ENLACE; O, S, ENTRE OTROS; Y ES BENZOXAZOLILO, BENZOTIAZOLILO, PIRIDILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N2,N4-BIS-(3,5-DIMETOXIBENCIL)PIRIDO[2,3-d]PIRIMIDIN-2,4-DIAMINA; N4-(3,5-DIMETOXIBENCIL)-N2-(2-PIRIDIN-4-ILETIL)PIRIDO[2,3-d]PIRIMIDIN-2,4-DIAMINA Y 2-(3-{3-[4-(3,4-DIMETOXIBENCILAMINO)PIRIDO[2,3-d]PIRIMIDIN-2-ILAMINO]-PROPIL}FENIL)PROPAN-2-OL; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE AGRAGACION PLAQUETARIA, ANGIOGENESIS VASCULAR, CANCER, ENTRE OTRAS
PE2005000028A 2003-12-16 2005-01-03 PIRIDO[2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2 PE20050681A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52999403P 2003-12-16 2003-12-16

Publications (1)

Publication Number Publication Date
PE20050681A1 true PE20050681A1 (es) 2005-10-04

Family

ID=34710150

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000028A PE20050681A1 (es) 2003-12-16 2005-01-03 PIRIDO[2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2

Country Status (39)

Country Link
US (1) US20070135457A1 (es)
EP (1) EP1697356B1 (es)
JP (1) JP4073944B2 (es)
KR (1) KR100816179B1 (es)
CN (1) CN100439366C (es)
AP (1) AP2006003632A0 (es)
AR (1) AR046766A1 (es)
AT (1) ATE387446T1 (es)
AU (1) AU2004303609A1 (es)
BR (1) BRPI0417663A (es)
CA (1) CA2549510A1 (es)
CL (1) CL2008001920A1 (es)
DE (1) DE602004012154T2 (es)
DK (1) DK1697356T3 (es)
EA (1) EA010424B1 (es)
EC (1) ECSP066643A (es)
ES (1) ES2299888T3 (es)
GE (1) GEP20094720B (es)
GT (1) GT200400268A (es)
HN (1) HN2004000538A (es)
HR (1) HRP20080142T3 (es)
IL (1) IL175813A0 (es)
IS (1) IS8474A (es)
MA (1) MA28270A1 (es)
MX (1) MXPA06006777A (es)
NL (1) NL1027787C2 (es)
NO (1) NO20063231L (es)
PE (1) PE20050681A1 (es)
PL (1) PL1697356T3 (es)
PT (1) PT1697356E (es)
RS (1) RS50575B (es)
SI (1) SI1697356T1 (es)
SV (1) SV2005001979A (es)
TN (1) TNSN06186A1 (es)
TW (1) TWI291961B (es)
UA (1) UA83091C2 (es)
UY (1) UY28671A1 (es)
WO (1) WO2005061497A1 (es)
ZA (1) ZA200604970B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601713B2 (en) * 2005-12-15 2009-10-13 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
KR20090098783A (ko) * 2006-09-21 2009-09-17 토시키 오구로 경조직 재생 촉진제
JP5472638B2 (ja) * 2008-03-18 2014-04-16 日産化学工業株式会社 1−(置換フェニル)−1−置換シリルエーテル、アルコールまたはケトンの製造方法および中間体
EP2355657A4 (en) * 2008-10-31 2012-05-09 Corridor Pharmaceuticals Inc Compositions and methods for treating endothelial dysfunction
EP2456440B1 (en) 2009-07-22 2015-08-19 Merck Sharp & Dohme Corp. Quinolinone pde2 inhibitors
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
EP2699577A1 (en) 2011-04-20 2014-02-26 Glaxo Group Limited Tetrahydropyrazolo [1,5 -a]pyrimidine as anti -tuberculosis compounds
AU2013253516B2 (en) 2012-04-25 2017-10-12 Takeda Pharmaceutical Company Limited Nitrogenated heterocyclic compound
WO2014010732A1 (ja) 2012-07-13 2014-01-16 武田薬品工業株式会社 複素環化合物
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
WO2015012328A1 (ja) * 2013-07-24 2015-01-29 武田薬品工業株式会社 複素環化合物
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 製剤および医薬組成物
US20170245538A1 (en) * 2014-08-01 2017-08-31 Firmenich Sa Solid dispersion of amide flavor compounds
RU2702732C1 (ru) 2014-12-06 2019-10-10 Интра-Селлулар Терапиз, Инк. Органические соединения
HK1243936A1 (zh) 2014-12-06 2018-07-27 Intra-Cellular Therapies, Inc. 有机化合物
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
EP3291817B1 (en) 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
US10647727B2 (en) 2015-06-25 2020-05-12 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
CA3083176A1 (en) 2017-11-23 2019-05-31 Oslo University Hospital Hf Treatment of tachycardia
CN109758458B (zh) * 2019-03-05 2021-02-23 中国人民解放军陆军军医大学第二附属医院 抑制Crif1与PKA相互作用的化合物的应用
WO2022187411A1 (en) * 2021-03-02 2022-09-09 Kumquat Biosciences Inc. Heterocycles and uses thereof
JP2025515285A (ja) 2022-04-20 2025-05-14 カムクワット バイオサイエンシーズ インコーポレイテッド 大環状複素環及びその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2749344A (en) * 1953-01-02 1956-06-05 Burroughs Wellcome Co Pyrimidine compounds
US2926166A (en) * 1954-01-04 1960-02-23 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
US3021332A (en) * 1954-01-04 1962-02-13 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
US2924599A (en) * 1956-07-16 1960-02-09 Anchor Chemical Company Ltd Derivatives of 1:3:5-triazanaphthalene
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
US3288792A (en) * 1962-07-05 1966-11-29 Burroughs Wellcome Co Method of preparing 2, 4-diamino-6-alkylpyrido (2, 3-d) pyrimidines
DE3422824A1 (de) * 1984-06-20 1986-01-02 Celamerck Gmbh & Co Kg, 6507 Ingelheim Neue herbizid wirksame sulfonylharnstoffe
US6194166B1 (en) * 1993-05-24 2001-02-27 Takara Shuzo Co., Ltd. Gene regulating aureobasidin sensitivity
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US6262059B1 (en) * 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4

Also Published As

Publication number Publication date
EP1697356B1 (en) 2008-02-27
HN2004000538A (es) 2008-02-21
UY28671A1 (es) 2005-07-29
NL1027787C2 (nl) 2006-03-09
EP1697356A1 (en) 2006-09-06
CN1894245A (zh) 2007-01-10
AP2006003632A0 (en) 2006-06-30
TNSN06186A1 (fr) 2007-11-15
BRPI0417663A (pt) 2007-04-03
EA010424B1 (ru) 2008-08-29
ZA200604970B (en) 2007-11-28
ECSP066643A (es) 2006-10-25
TW200522952A (en) 2005-07-16
SV2005001979A (es) 2005-12-13
PT1697356E (pt) 2008-05-05
DK1697356T3 (da) 2009-01-12
US20070135457A1 (en) 2007-06-14
JP2007513996A (ja) 2007-05-31
CA2549510A1 (en) 2005-07-07
AR046766A1 (es) 2005-12-21
NO20063231L (no) 2006-07-11
GEP20094720B (en) 2009-06-25
MXPA06006777A (es) 2006-08-23
ATE387446T1 (de) 2008-03-15
ES2299888T3 (es) 2008-06-01
HRP20080142T3 (en) 2008-06-30
JP4073944B2 (ja) 2008-04-09
KR20060105776A (ko) 2006-10-11
GT200400268A (es) 2005-09-20
UA83091C2 (en) 2008-06-10
IS8474A (is) 2006-05-18
DE602004012154D1 (de) 2008-04-10
TWI291961B (en) 2008-01-01
NL1027787A1 (nl) 2005-06-21
PL1697356T3 (pl) 2008-07-31
MA28270A1 (fr) 2006-11-01
RS50575B (sr) 2010-05-07
CL2008001920A1 (es) 2008-10-17
WO2005061497A1 (en) 2005-07-07
KR100816179B1 (ko) 2008-03-28
CN100439366C (zh) 2008-12-03
SI1697356T1 (sl) 2008-06-30
AU2004303609A1 (en) 2005-07-07
IL175813A0 (en) 2006-10-05
EA200600973A1 (ru) 2006-10-27
DE602004012154T2 (de) 2009-03-12

Similar Documents

Publication Publication Date Title
PE20050681A1 (es) PIRIDO[2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
PE20050691A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20060600A1 (es) Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
PE20090887A1 (es) DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20090835A1 (es) Derivados de quinazolina como inhibidores de la pi3 quinasa
CR8744A (es) Compuestos terapeuticos
NZ594385A (en) Aminopyrimidines useful as kinase inhibitors
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
PE20080527A1 (es) Derivado de pirimidina como inhibidor de la fosfatidilinositol 3-quinasa (pi3k)
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
EA200600315A1 (ru) Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения
PE20070021A1 (es) Compuestos triazolopiridinas como antagonistas de receptor canabinoide 1
PE20051171A1 (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed